Published in Vaccine Weekly, February 16th, 2011
Chandini Portteus, Komen for the Cure's vice president of research, evaluation and scientific programs, also testified that Komen is concentrating its research funding across many areas, with a focus on prevention and early detection; novel and personalized treatments for aggressive and metastatic cancers, and disparities in breast...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.